

B1
cont
set forth illustratively in SEQ ID NO:786, or portions or variants thereof. Such compositions may be used, for example, in the diagnosis, prevention, and treatment of diseases such as lung cancer.

In the Claims:

Please cancel claims 1-2, 4-60, 63 and 64.

Please amend claims 62, 65, and 66 to read as follows:

B2
62. (Amended) An isolated polypeptide comprising the amino acid sequence

of SEQ ID NO:786, or a fragment thereof comprising at least 20 contiguous amino acid residues of SEQ ID NO:786.

65. (Amended) A composition comprising a polypeptide of any one of claims 61 or 62 and a physiologically acceptable carrier.

B3
66. (Amended) A composition comprising a polypeptide of any one of claims 61 or 62 and a non-specific immune response enhancer.

REMARKS

Favorable reconsideration of the subject application is respectfully requested in view of the above amendments and the following remarks. Claims 1-2, 4-66 are pending in the application. Claims 1-2, 4-60, 63 and 64 have been cancelled. Claims 65 and 66 have been amended accordingly. Claim 62 has been amended to more clearly recite the claimed subject matter. Support for the amendment may be found in the specification and claims as originally filed, and the amendment does not constitute new matter. Support for fragments of SEQ ID NO:786 comprising at least 20 contiguous amino acid residues is provided, for example, on page 41, lines 6-9. The amendment is not to be construed as acquiescence to any rejection and is made without prejudice to prosecution of any subject matter modified by the amendment in a related divisional, continuation, or continuation-in-part application.